<unk>  (trade name Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of March 2022, it is under review for approval for uterine fibroids and endometriosis and is in phase II clinical studies for adenomyosis.
Linzagolix
Lazaretto
Ketotifen
Maralixibat chloride
Ladostigil
Lumasiran
Tesamorelin
Mirabegron